Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13130992 | 0.91 | HPGD (0.33) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1930873 | 0.82 | DDB1 (0.44) | HPGDALDH1A1ALDH2 | |
| SCHEMBL13131098 | 0.81 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13131104 | 0.78 | CTRB1 (0.37) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13130988 | 0.76 | DDB1 (0.34) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13131053 | 0.76 | DDB1 (0.34) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL24279365 | 0.74 | SCN1A (0.46) | HPGDALDH1A1MAPTKMT2AHTT | |
| SCHEMBL12906776 | 0.73 | NPC1 (0.33) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13131164 | 0.73 | ACHE (0.31) | ALDH1A1 | |
| SCHEMBL10174373 | 0.72 | SMN1; SMN2 (0.43) | HPGDALDH1A1MAPTMAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045414-B2 | Pyrrolidin-2-ones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045414-B2 | Pyrrolidin-2-ones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| EP-2346852-B1 | PYRROLIDIN-2-ONES AS HDM2 LIGANDS | BOEHRINGER INGELHEIM INT (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | PRIAXON AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | PRIAXON AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8119623-B2 | Pyrrolidin-2-ones | PRIAXON AG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119623-B2 | Pyrrolidin-2-ones | PRIAXON AG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028862-A1 | PYRROLIDIN-2-ONES AS HDM2 LIGANDS | PRIAXON AG (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | ING2, HMGB2, API5 | HPGD 1000/4885ALDH1A1 1442/4885MAPT 623/4885 |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | ING2, HMGB2, API5 | HPGD 1000/4885ALDH1A1 1442/4885MAPT 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.